Barbara Mroczko1, Magdalena Groblewska2, Marzena Zboch3, Paweł Muszyński4, Agata Zajkowska4, Renata Borawska4, Maciej Szmitkowski5, Johannes Kornhuber6, Piotr Lewczuk6. 1. Department of Neurodegeneration Diagnostics, Medical University of Białystok, Poland Department of Biochemical Diagnostics, University Hospital in Białystok, Poland. 2. Department of Biochemical Diagnostics, University Hospital in Białystok, Poland. 3. Research-Scientific-Didactic Centre of Dementia-Related Diseases, Wrocław Medical University, Ścinawa, Poland. 4. Department of Neurodegeneration Diagnostics, Medical University of Białystok, Poland. 5. Department of Biochemical Diagnostics, University Hospital in Białystok, Poland Department of Biochemical Diagnostics, Medical University of Białystok, Poland. 6. Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
Abstract
BACKGROUND: The correlations between pathology of neurodegenerative diseases, especially Alzheimer's disease (AD), and concentrations of neuronal calcium sensor proteins, such as visinin-like protein 1 (VILIP-1), in cerebrospinal fluid (CSF) have been discussed in the literature but its utility as biomarker of AD in comparison with mild cognitive impairment (MCI) has not been studied yet. OBJECTIVE: Therefore, the aim of our study was to assess the clinical utility of the measurement of CSF concentrations of VILIP-1 in patients with AD, MCI subjects, and non-demented controls. The clinical and neuropsychological diagnoses were supported by CSF biomarkers of neurochemical dementia diagnostics: decreased concentrations of Aβ1-42 and/or Aβ42/40 ratio and increased concentrations of Tau and pTau181 proteins. METHODS: The study included 33 AD patients, 15 subjects with MCI, and 18 elderly individuals without cognitive deficits. The CSF concentrations of biomarkers tested were determined by using the ELISA method. RESULTS: Concentrations of VILIP-1 in CSF were significantly higher in AD patients compared to the MCI subjects and elderly individuals without cognitive impairment. Increased concentrations of VILIP-1 correlated significantly with reduced Aβ42/40 ratio and higher pTau181 in AD group. CONCLUSION: Our findings suggest that VILIP-1 may play a role in the AD pathophysiology and is a good candidate for dynamic biomarker of AD, although this issue requires further investigation.
BACKGROUND: The correlations between pathology of neurodegenerative diseases, especially Alzheimer's disease (AD), and concentrations of neuronal calcium sensor proteins, such as visinin-like protein 1 (VILIP-1), in cerebrospinal fluid (CSF) have been discussed in the literature but its utility as biomarker of AD in comparison with mild cognitive impairment (MCI) has not been studied yet. OBJECTIVE: Therefore, the aim of our study was to assess the clinical utility of the measurement of CSF concentrations of VILIP-1 in patients with AD, MCI subjects, and non-demented controls. The clinical and neuropsychological diagnoses were supported by CSF biomarkers of neurochemical dementia diagnostics: decreased concentrations of Aβ1-42 and/or Aβ42/40 ratio and increased concentrations of Tau and pTau181 proteins. METHODS: The study included 33 ADpatients, 15 subjects with MCI, and 18 elderly individuals without cognitive deficits. The CSF concentrations of biomarkers tested were determined by using the ELISA method. RESULTS: Concentrations of VILIP-1 in CSF were significantly higher in ADpatients compared to the MCI subjects and elderly individuals without cognitive impairment. Increased concentrations of VILIP-1 correlated significantly with reduced Aβ42/40 ratio and higher pTau181 in AD group. CONCLUSION: Our findings suggest that VILIP-1 may play a role in the AD pathophysiology and is a good candidate for dynamic biomarker of AD, although this issue requires further investigation.
Authors: Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber Journal: World J Biol Psychiatry Date: 2017-10-27 Impact factor: 4.132
Authors: Caitlin M Kirkwood; Matthew L MacDonald; Tadhg A Schempf; Anil V Vatsavayi; Milos D Ikonomovic; Jeremy L Koppel; Ying Ding; Mai Sun; Julia K Kofler; Oscar L Lopez; Nathan A Yates; Robert A Sweet Journal: J Neuropathol Exp Neurol Date: 2016-02 Impact factor: 3.685
Authors: Yuk Yee Leung; Jon B Toledo; Alexey Nefedov; Robi Polikar; Nandini Raghavan; Sharon X Xie; Michael Farnum; Tim Schultz; Young Baek; Vivianna V Deerlin; William T Hu; David M Holtzman; Anne M Fagan; Richard J Perrin; Murray Grossman; Holly D Soares; Mitchel A Kling; Matthew Mailman; Steven E Arnold; Vaibhav A Narayan; Virginia M-Y Lee; Leslie M Shaw; David Baker; Gayle M Wittenberg; John Q Trojanowski; Li-San Wang Journal: Alzheimers Dement (Amst) Date: 2015-09-01
Authors: María Victoria Zelaya; Estela Pérez-Valderrama; Xabier Martínez de Morentin; Teresa Tuñon; Isidro Ferrer; María Rosario Luquin; Joaquín Fernandez-Irigoyen; Enrique Santamaría Journal: Oncotarget Date: 2015-11-24
Authors: Alejandro López-Hurtado; Daniel F Burgos; Paz González; Xose M Dopazo; Valentina González; Alberto Rábano; Britt Mellström; Jose R Naranjo Journal: Mol Brain Date: 2018-03-09 Impact factor: 4.041